Bastian Patrick J, Yegnasubramanian Srinivasan, Palapattu Ganesh S, Rogers Craig G, Lin Xiaohui, De Marzo Angelo M, Nelson William G
The James Buchanan Brady Urological Institute, Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231-1000, USA.
Eur Urol. 2004 Dec;46(6):698-708. doi: 10.1016/j.eururo.2004.07.022.
CpG island hypermethylation may be one of the earliest somatic genome alterations to occur during the development of multiple cancers. Recently, aberrant methylation patterns for different tumors have been reported. We present a comprehensive review of the literature describing the role of CpG island hypermethylation of DNA from prostatic tissue and bodily fluids from men with prostate cancer. We reviewed the literature to evaluate CpG island hypermethylation in tissue and bodily fluids of men with primary and metastatic prostate cancer. Additionally, we reviewed the literature with respect to CpG island hypermethylation patterns in other urological malignancies. Using modern analytic methods, CpG island hypermethylation detection can be achieved. In men with prostate cancer, correlations between specific gene regulatory region hypermethylation analyses and Gleason score, pathologic stage and tumor recurrence have been demonstrated. CpG island hypermethylation may serve as a useful molecular biomarker for the detection and diagnosis of patients with prostate cancer.
CpG岛高甲基化可能是多种癌症发生过程中最早出现的体细胞基因组改变之一。最近，已有关于不同肿瘤异常甲基化模式的报道。我们对描述前列腺组织和前列腺癌男性体液中DNA的CpG岛高甲基化作用的文献进行了全面综述。我们回顾文献以评估原发性和转移性前列腺癌男性的组织和体液中的CpG岛高甲基化情况。此外，我们还回顾了其他泌尿系统恶性肿瘤中CpG岛高甲基化模式的相关文献。使用现代分析方法，可以实现CpG岛高甲基化检测。在前列腺癌男性中，特定基因调控区域高甲基化分析与 Gleason评分、病理分期和肿瘤复发之间的相关性已得到证实。CpG岛高甲基化可能作为检测和诊断前列腺癌患者的有用分子生物标志物。
